ArticleBreast cancer research and treatment2026
Association of cumulative lifetime estrogen exposure and reproductive factors with breast cancer molecular subtype among Nigerian women in the MEND study.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
purposeCumulative lifetime endogenous estrogen exposure (CLEEE) is an established breast cancer (BC) risk factor, yet Nigeria faces increasing BC incidence and mortality despite reproductive patterns typically associated with lower estrogen exposure. We evaluated the association of endogenous estrogen exposure and BC risk in this population.
methodsWe analyzed 609 Nigerian BC cases and 609 controls from the MEND case-control study to examine associations between CLEEE and BC risk by molecular subtype. CLEEE was defined as time from menarche to menopause (or enrollment), minus pregnancy duration; a breastfeeding-adjusted measure (CLEEE-b) subtracted breastfeeding duration.
resultsMost cases were grade 2 (67.2%) or grade 3 (27.9%), with 42.8% triple-negative breast cancer (TNBC), 33.7% luminal A, 12.6% HER2-enriched, and 10.9% luminal B. Compared with controls (medians), cases had lower BMI (25.4 vs. 26.7, p < 0.001), earlier menarche (mean: 14.9 vs. 15.2 years, p < 0.001), and higher CLEEE (330 vs. 321 months, p < 0.018) and CLEEE-b (273 vs. 264 months, p = 0.043). In multivariable models adjusting for BMI and menopausal status, each standard deviation increase in CLEEE was associated with 33% higher BC odds (aOR 1.33, 95% CI 1.13-1.57), with stronger association for postmenopausal women (aOR: 1.62, 95% CI: 1.22-2.19), women with BMI ≥ 3025 (aOR: 1.52, 95% CI: 1.07-2.20), and for TNBC (highest vs. low CLEEE tertile: aOR 1.90, 95% CI 1.12-3.26). Associations for CLEEE-b remained significant but modestly attenuated.
conclusionHigher CLEEE was associated with increased BC odds, particularly for TNBC. Larger studies among African women are needed to confirm these associations to inform prevention strategies.
Indexed as
Identifiers
42223563What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.